The nomination committee’s proposal regarding election of board members of Bio-Works

The nomination committee of Bio-Works Technologies has decided to submit the following proposal regarding election of board members at the annual general meeting of Bio-Works on May 26, 2023.

• The board shall have four members (five at present)
• Re-election of directors Peter Ehrenheim, Kirsti Gjellan, Johan Sedihn and Peter Nählstedt.
• Re-election of Peter Ehrenheim as chair of the board.

Director Patrick Van De Velde has declined re-election.

The nomination committee prior to the 2023 annual general meeting consist of:

• Staffan Persson (appointed by Nortal Investments AB/Swedia Invest AB)
• Erik Åfors (Calyptra AB)
• Dariush Hosseinian (Karkas Capital AB)
• Peter Ehrenheim (chair of the board of Bio-Works)

Staffan Persson is appointed chair of the nomination committee.

The complete proposal will appear further in the notice to the annual general meeting.

Contacts
For more information, please visit the Bio-Works homepage at,www.bio-works.comor contact: Jonathan Royce, CEO, e-mail:jonathan.royce@bio-works.com, phone: +46 70 1434143.

About Bio-Works
Bio-Works enables scientists to achieve their purification goals, from laboratory research to large scale bioprocess production. Our vision is a biotech industry that embraces, develops and builds on new methods and novel ideas. WorkBeads™, Bio-Works’ next-generation, agarose-based products, are used to purify proteins, peptides and other biomolecules, resulting in purer therapies and safer diagnostics. Through collaboration with customers and partners, we develop purification solutions that make important medicines available and accessible to everyone.

Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Nasdaq First North (“BIOWKS”), and FNCA Sweden AB, +46 (0) 8-528 00 399,info@fnca.se, is appointed Certified Adviser. For more information,www.bio-works.com.